Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

compensation expense related to employee stock option and restricted stock awards of $7.5 million in the third quarter of 2009 and $22.6 million for the first nine months of 2009, compared with $8.2 million and $24.7 million, respectively, for the same periods of 2008.

Research and development (R&D) expenses increased to $105.4 million in the third quarter of 2009 from $72.1 million in the comparable quarter of 2008, and to $280.0 million in the first nine months of 2009 from $200.3 million in the same period of 2008. In the third quarter and first nine months of 2009, the Company incurred higher R&D costs primarily related to additional R&D headcount, clinical development costs for ARCALYST, VEGF Trap-Eye, and monoclonal antibodies, research and preclinical development costs associated with the antibody programs, and facility-related costs to support expanded R&D activities.

Selling, general, and administrative (SG&A) expenses increased to $12.8 million in the third quarter of 2009 from $11.1 million in the comparable quarter of 2008, and to $35.9 million in the first nine months of 2009 from $35.7 million in the same period of 2008. In the third quarter and for the first nine months of 2009, the Company incurred higher compensation and facility-related expenses due primarily to increases in administrative headcount to support the expanded research and development activities, higher patent-related costs, and higher expenses related to ARCALYST® (rilonacept), partially offset by lower market research costs related to various programs and a decrease in recruitment costs for administrative headcount.

Other Income and Expense

Investment income decreased to $0.9 million in the third quarter of 2009 from $3.7 million in the comparable quarter of 2008 and to $3.9 million in the first nine months of 2009 compared to $15.5 million in the first nine months of 2008. The decrease in investme
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... New high priced hepatitis C drugs will increase federal ... to $5.8 billion next year, according to a new ... the Pharmaceutical Care Management Association (PCMA). Milliman projects that ... as 8.6 percent in 2015 as a result of ... The study finds that the majority of new ...
(Date:7/29/2014)... Numotion,s Board of Directors has announced that as ... the company,s new Chief Executive Officer. Swinford ... where he worked primarily for GE Healthcare Services, running businesses ... billion. His most recent position was as President and CEO ... thrilled to join Numotion," said Mike Swinford . "I ...
(Date:7/29/2014)... July 29, 2014  Roche (SIX: RO, ROG; OTCQX: ... Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by ... unique ways Roche is partnering with customers to redefine ... tell us every day that they,re looking for a ... in their labs and offices," said Jack Phillips ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
(Date:7/29/2014)... 30, 2014 Dignity Sciences Limited, a ... of a Phase I trial with DS107G, an oral ... study was a randomized, placebo-controlled, double-blind, single-ascending and multiple ... pharmacokinetics and effect of food on DS107G in healthy ... profile of DGLA following both single and multiple oral ...
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... program was created by a holistic nutritional and functional medicine ... way of overcoming this problem. , Karen suffered from leaky ... so much time to develop this unique treatment. , ... her method, with sufferers from all around the world. The ...
(Date:7/29/2014)... Washington, New York (PRWEB) July 29, 2014 ... to protecting the rights of victims injured by defective ... lawsuit has been filed by plaintiffs in Canada who ... risk of cardiovascular events with the low testosterone ... filed on July 22, 2014 in the Ontario Superior ...
Breaking Medicine News(10 mins):Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3
... Fla., Dec. 13 The Quantum Group,Inc. (Amex: ... it,has completed its registered public offering, raising $13.2 ... it has initiated trading,on the American Stock Exchange ... the symbol "QGP.U." In addition, Quantum common shares,formerly ...
... for the Hospital,s ... State-of-the-Art Cardiothoracic Center, SANTA CLARA, Calif., Dec. ... a new network,infrastructure to support a trust-wide Picture Archiving ... Hospitals, part,of the NHS Foundation Trust in Essex, United ...
... plan services for members, ROCKVILLE, Md., Dec. ... of comprehensive dental plans and administration, has,announced a ... the,nation,s leading integrated health plan provider. GDS will ... and,call center support to Kaiser Permanente Northwest,s 180,000 ...
... NEW YORK, Dec. 13 Getting in shape shouldn,t ... a public health,advocate and veteran of the fitness industry. ... Year, Holland has developed a novel fitness,program to help ... Ease-In Longevity program allows people to "ease into," exercise,going ...
... to 100,000-fold, study finds , , THURSDAY, Dec. 13 (HealthDay News) ... team reports that tiny fibers commonly found in semen drastically ... , According to a study in the Dec. 14 issue ... then ferry it to target cells, increasing its ability to ...
... human spine evolved differently in males and females in ... carrying a baby, according to research spearheaded at The ... are documented for the first time in the Dec. ... adaptation first appeared at least two million years ago, ...
Cached Medicine News:Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 3Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 2Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 3Health News:Fitness Guru Offers Novel Exercise Program and Tips to Stick with Exercise in the New Year 2Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Adapting to pregnancy played key role in human evolution, study shows 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: